{"id":"9fb5ecdc2ede","type":"article","url":"https://hartvaat.nl/2025/12/29/effect-van-cilostazol-op-de-prognose-van-perifeer-arterieel-vaatlijden-bij-diabe/","title":"Effect van cilostazol op de prognose van perifeer arterieel vaatlijden bij diabetes in Korea","title_en":"Effects of cilostazol on the prognosis of lower extremity peripheral arterial disease in patients with diabetes mellitus in Korea: A nationwide population-based study","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["credence-trial","fidelio-dkd","soul-trial"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01532-1/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01532-1/fulltext","authors":["Shinje Moon","Sangmo Hong","Kyungdo Han","Cheol-Young Park"],"significance":5,"published":"2025-12-29","source_date":"2025-12-29","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"A Korean nationwide population-based study analysed the long-term prognostic effects of cilostazol in patients with diabetes and lower extremity peripheral arterial disease. The findings inform the use of this PDE3 inhibitor beyond symptomatic walking distance improvement.","created":"2026-07-03T10:25:38Z","updated":"2026-07-03T13:25:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Cilostazol vergroot de pijnvrije loopafstand bij perifeer arterieel vaatlijden. Het effect op de prognose bij patiënten met diabetes was onduidelijk. Deze Koreaanse populatiestudie analyseerde de effecten op de langetermijnuitkomsten.","abstract_original":"Cilostazol increases pain-free walking distance in patients with lower extremity peripheral arterial disease (PAD). However, the effect of cilostazol on the prognosis of PAD in patients with diabetes remains unclear. We analyzed its effects on the long-term prognosis of Korean patients with diabetes and lower extremity PAD."}